Trial Profile
Safety and efficacy of ledipasvir/sofosbuvir in prevoiusly untreated non-corrhotic patients with HCV genotype 1 infection: A prospective RUA-VHC regitry study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 23 Apr 2018 New trial record
- 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections